<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01381172</url>
  </required_header>
  <id_info>
    <org_study_id>CP OPT2009-009</org_study_id>
    <secondary_id>G030099</secondary_id>
    <nct_id>NCT01381172</nct_id>
  </id_info>
  <brief_title>Evaluate Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure: FIX-HF-5C</brief_title>
  <acronym>FIX-HF-5C</acronym>
  <official_title>Evaluation of the Safety and Efficacy of the OPTIMIZER® System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%: FIX-HF-5C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Impulse Dynamics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Impulse Dynamics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this investigation is to evaluate the safety and effectiveness of the&#xD;
      OPTIMIZER® System in subjects with medically refractory moderate-to-severe heart failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Impulse Dynamics FIX-HF-5C Study is a prospective, multicenter, randomized study to&#xD;
      evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered&#xD;
      by the implantable OPTIMIZER System in patients with NYHA class III and IV heart failure and&#xD;
      an ejection fraction 25-45%. The study will involve the recruitment of 160 subjects at a&#xD;
      total of up to 60 sites.&#xD;
&#xD;
      Those subjects who fulfill all inclusion and exclusion criteria based upon baseline test&#xD;
      results will be randomly assigned in a 1:1 ratio to either the OPTIMIZER System plus optimal&#xD;
      medical therapy (OMT) or to a control group receiving OMT alone. All randomized subjects will&#xD;
      be followed for 24 weeks and shall receive the same study related assessments throughout the&#xD;
      course of the study. In addition, all subjects will continue to receive OMT for the treatment&#xD;
      of their heart failure. Mortality will be reported out to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 19, 2019</completion_date>
  <primary_completion_date type="Actual">March 19, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak VO2</measure>
    <time_frame>24 weeks</time_frame>
    <description>Exercise tolerance quantified by peak VO2 measured with cardiopulmonary exercise stress testing (CPX) and evaluated by a blinded core lab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minnesota Living With Heart Failure (MLWHF) Questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in quality of life at 24 weeks compared to baseline, as assessed by the Minnesota Living with Heart Failure (MLWHF) Questionnaire. The MLWHFQ score could range from 0 to 105, with higher scores indicating more significant impairment in health-related quality of lif</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak VO2 With Respiratory Exchange Ratio (RER)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Peak VO2 with change in respiratory exchange ratio (RER) included as a covariate, as measured by a blinded core lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA</measure>
    <time_frame>24 weeks</time_frame>
    <description>Heart failure class, as assessed by the New York Heart Association (NYHA) classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak VO2 With a Peak RER of ≥1.05</measure>
    <time_frame>24 weeks</time_frame>
    <description>Peak VO2 in an analysis that only includes tests with a peak RER of ≥1.05.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>6 Minute Hall Walk</measure>
    <time_frame>24 weeks</time_frame>
    <description>Distance walked in 6 minutes</description>
  </other_outcome>
  <other_outcome>
    <measure>VE/VCO2</measure>
    <time_frame>24 weeks</time_frame>
    <description>VE/VCO2 measured during cardiopulmonary stress testing (CPX) and evaluated by a blinded core lab.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>NYHA Class III Heart Failure</condition>
  <condition>NYHA Class IV Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optimizer System</intervention_name>
    <description>The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>CCM therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention: Optimal medical therapy</intervention_name>
    <description>The control group receives optimal medical therapy only.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who are 18 years of age or older&#xD;
&#xD;
          2. Subjects who are either male or female. Females of childbearing potential must be&#xD;
             using a medically approved method of birth control and must agree to continue to use&#xD;
             birth control throughout the study, or must be surgically sterilized (tubal ligation,&#xD;
             hysterectomy) or post-menopausal for at least 1 year.&#xD;
&#xD;
          3. Condition&#xD;
&#xD;
               1. Subjects who have a baseline ejection fraction greater than or equal to 25% and&#xD;
                  less than or equal to 45% by echocardiography determined by the echocardiography&#xD;
                  core laboratory.&#xD;
&#xD;
               2. Subjects who have been treated for heart failure for at least 90 days (including&#xD;
                  treatment with a β-blocker for at least 90 days unless the subject is intolerant)&#xD;
                  and are in New York Heart Association functional Class III and IV at the time of&#xD;
                  enrollment.&#xD;
&#xD;
               3. Subjects receiving appropriate, stable medical therapy during the 30 days prior&#xD;
                  to enrollment for treatment of heart failure according to the region- specific&#xD;
                  guideline recommendations. For patients with EF≤35%, this regimen shall consist&#xD;
                  of the appropriate doses of diuretics, ACE-inhibitor or angiotensin II receptor&#xD;
                  blocker and β-blocker. Stable is defined as no more than a 100% increase or 50%&#xD;
                  decrease in dose.&#xD;
&#xD;
               4. Subjects who, in the opinion of the Principal Investigator (based on the current&#xD;
                  guidelines for clinical practice ), have a clinical indication for an implanted&#xD;
                  cardiac defibrillator (ICD, e.g., EF≤35%) and/or pacemaker, must have an existing&#xD;
                  device or agree to undergo implantation of such a device unless the patient&#xD;
                  refuses to undergo the implantation of such device for personal reasons.&#xD;
&#xD;
               5. Subjects who are willing and able to return for all follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects whose baseline peak VO2 is &lt;9 or &gt;20 ml O2/min/kg.&#xD;
&#xD;
          2. Subjects who have a potentially correctible cause of heart failure, such as valvular&#xD;
             heart disease or congenital heart disease.&#xD;
&#xD;
          3. Subjects who have clinically significant angina pectoris, consisting of angina during&#xD;
             daily life (i.e., Canadian Cardiovascular Society Angina score of II or more), an&#xD;
             episode of unstable angina within 30 days of enrollment, or angina and/or ECG changes&#xD;
             during exercise testing performed during baseline evaluation.&#xD;
&#xD;
          4. Subjects who have been hospitalized for heart failure which required the use of&#xD;
             inotropic support within 30 days of enrollment.&#xD;
&#xD;
          5. Subjects who have a clinically significant amount of ambient ectopy, defined as more&#xD;
             than 8,900 PVCs per 24 hours on baseline Holter monitoring.&#xD;
&#xD;
          6. Subjects having a PR interval greater than 375 ms.&#xD;
&#xD;
          7. Subjects who have chronic (permanent or persistent) atrial fibrillation or atrial&#xD;
             flutter or those cardioverted within 30 days of enrollment.&#xD;
&#xD;
          8. Subjects whose exercise tolerance is limited by a condition other than heart failure&#xD;
             (e.g., angina, COPD, peripheral vascular disease, orthopedic or rheumatologic&#xD;
             conditions) or who are unable to perform baseline stress testing.&#xD;
&#xD;
          9. Subjects who are scheduled for a CABG or a PTCA procedure, or who have undergone a&#xD;
             CABG procedure within 90 days or a PTCA procedure within 30 days of enrollment.&#xD;
&#xD;
         10. Subjects who have a biventricular pacing system, an accepted indication for such a&#xD;
             device, or a QRS width of 130ms or greater.&#xD;
&#xD;
         11. Subjects who have had a myocardial infarction within 90 days of enrollment.&#xD;
&#xD;
         12. Subjects who have mechanical tricuspid valve.&#xD;
&#xD;
         13. Subjects who have a prior heart transplant.&#xD;
&#xD;
         14. Subjects on dialysis.&#xD;
&#xD;
         15. Subjects who are participating in another experimental protocol.&#xD;
&#xD;
         16. Subjects who are unable to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Burkhoff, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Impulse Dynamics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Consultants</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates of Mesa</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chan Heart Rhythm Institute</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Heart &amp; Rhythm Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pima Heart</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona Sarver Heart Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale - New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital - Pepin Heart Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Medical Group - Midwest Heart Foundation</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Adventist Hospital</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <zip>20912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elizabeth's Medical Center</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Medical Center - Cardiovascular Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryan Heart LGH</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>69506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lindner Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guthrie Medical Group</name>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <zip>18840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stern Cardiovascular Foundation</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Clinic</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Heart &amp; Vascular Institute</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Hanover</city>
        <state>Göttingen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz- und Gefässzentrum Bad Bevensen</name>
      <address>
        <city>Bad Bevensen</city>
        <zip>29549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Berlin - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus-Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASKLEPIOS Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UKE - Universitäres Herzzentrum GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Univ. München - Grosshadern</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.impulse-dynamics.com/us/</url>
    <description>Impulse Dynamics Website</description>
  </link>
  <reference>
    <citation>Kadish A, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R, Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y, Burkhoff D, Abraham WT. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J. 2011 Feb;161(2):329-337.e1-2. doi: 10.1016/j.ahj.2010.10.025. Erratum in: Am Heart J. 2011 Jun;161(6):1220.</citation>
    <PMID>21315216</PMID>
  </reference>
  <reference>
    <citation>Abraham WT, Burkhoff D, Nademanee K, Carson P, Bourge R, Ellenbogen KA, Parides M, Kadish A; FIX-HF-5 Investigators and Coordinators. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristics. Am Heart J. 2008 Oct;156(4):641-648.e1. doi: 10.1016/j.ahj.2008.05.019.</citation>
    <PMID>18926146</PMID>
  </reference>
  <reference>
    <citation>Neelagaru SB, Sanchez JE, Lau SK, Greenberg SM, Raval NY, Worley S, Kalman J, Merliss AD, Krueger S, Wood M, Wish M, Burkhoff D, Nademanee K. Nonexcitatory, cardiac contractility modulation electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm. 2006 Oct;3(10):1140-7. Epub 2006 Jul 8.</citation>
    <PMID>17018340</PMID>
  </reference>
  <reference>
    <citation>Abraham WT, Nademanee K, Volosin K, Krueger S, Neelagaru S, Raval N, Obel O, Weiner S, Wish M, Carson P, Ellenbogen K, Bourge R, Parides M, Chiacchierini RP, Goldsmith R, Goldstein S, Mika Y, Burkhoff D, Kadish A; FIX-HF-5 Investigators and Coordinators. Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. J Card Fail. 2011 Sep;17(9):710-7. doi: 10.1016/j.cardfail.2011.05.006. Epub 2011 Jun 22.</citation>
    <PMID>21872139</PMID>
  </reference>
  <reference>
    <citation>Abraham WT, Lindenfeld J, Reddy VY, Hasenfuss G, Kuck KH, Boscardin J, Gibbons R, Burkhoff D; FIX-HF-5C Investigators and Coordinators. A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with moderately reduced left ventricular ejection fraction and a narrow QRS duration: study rationale and design. J Card Fail. 2015 Jan;21(1):16-23. doi: 10.1016/j.cardfail.2014.09.011. Epub 2014 Oct 5.</citation>
    <PMID>25285748</PMID>
  </reference>
  <reference>
    <citation>Abraham WT, Kuck KH, Goldsmith RL, Lindenfeld J, Reddy VY, Carson PE, Mann DL, Saville B, Parise H, Chan R, Wiegn P, Hastings JL, Kaplan AJ, Edelmann F, Luthje L, Kahwash R, Tomassoni GF, Gutterman DD, Stagg A, Burkhoff D, Hasenfuß G. A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC Heart Fail. 2018 Oct;6(10):874-883. doi: 10.1016/j.jchf.2018.04.010. Epub 2018 May 10.</citation>
    <PMID>29754812</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>April 20, 2020</results_first_submitted>
  <results_first_submitted_qc>August 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2021</results_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Congestive Heart Failure</keyword>
  <keyword>Chronic heart disease</keyword>
  <keyword>Cardiac contractility modulation</keyword>
  <keyword>CCM</keyword>
  <keyword>CHF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 25, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01381172/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.&#xD;
Optimizer System: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.&#xD;
No intervention: Optimal medical therapy: The control group receives optimal medical therapy only.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.&#xD;
Optimizer System: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.&#xD;
No intervention: Optimal medical therapy: The control group receives optimal medical therapy only.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="74"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="160"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" lower_limit="32" upper_limit="85"/>
                    <measurement group_id="B2" value="60.0" lower_limit="28" upper_limit="87"/>
                    <measurement group_id="B3" value="60.7" lower_limit="58.5" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Peak VO2 (ml/kg/min)</title>
          <description>Peak VO2 measures the highest value of oxygen consumption measured during incremental exercise attained during an incremental exercise test, designed to bring the subject to the limit of their exercise tolerance.</description>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.36" spread="2.81"/>
                    <measurement group_id="B2" value="15.49" spread="2.61"/>
                    <measurement group_id="B3" value="15.425" spread="0.141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Minnesota Living with Heart Failure Questionnaire (MLWHFQ) score</title>
          <description>Minnesota Living with Heart Failure Questionnaire (MLWHFQ) score. There are 21 questions completed by the participant, with each response on a scale of 0-5. The total score ranges from 0 to 105, with higher scores indicating more significant impairment in health-related quality of life.</description>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.35" spread="23.36"/>
                    <measurement group_id="B2" value="56.42" spread="22.95"/>
                    <measurement group_id="B3" value="56.885" spread="0.28991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Class III</title>
          <description>Class I: Ordinary physical activity does not cause undue dyspnea or fatigue.&#xD;
Class II: Comfortable at rest. Ordinary physical activity results in dyspnea or fatigue.&#xD;
Class III: Comfortable at rest. Less than ordinary physical activity results in dyspnea or fatigue.&#xD;
Class IV: Symptoms of heart failure may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Class IV</title>
          <description>Class I: Ordinary physical activity does not cause undue dyspnea or fatigue.&#xD;
Class II: Comfortable at rest. Ordinary physical activity results in dyspnea or fatigue.&#xD;
Class III: Comfortable at rest. Less than ordinary physical activity results in dyspnea or fatigue.&#xD;
Class IV: Symptoms of heart failure may be present even at rest. If any physical activity is undertaken, discomfort is increased.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6 Minute Hall Walk (meters)</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="324.07" spread="89.71"/>
                    <measurement group_id="B2" value="316.85" spread="88.37"/>
                    <measurement group_id="B3" value="320.46" spread="0.94045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak VO2</title>
        <description>Exercise tolerance quantified by peak VO2 measured with cardiopulmonary exercise stress testing (CPX) and evaluated by a blinded core lab.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.&#xD;
Optimizer System: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.&#xD;
No intervention: Optimal medical therapy: The control group receives optimal medical therapy only.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak VO2</title>
          <description>Exercise tolerance quantified by peak VO2 measured with cardiopulmonary exercise stress testing (CPX) and evaluated by a blinded core lab.</description>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.28" spread="3.66"/>
                    <measurement group_id="O2" value="14.79" spread="3.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The FIX-HF-5C Study was a study designed to confirm the preliminary evidence reported in the FIX-HF-5 subgroup analysis demonstrating improvement in subjects with LVEF 25-45% and NYHA class III-IV. A Bayesian statistical approach was employed to leverage the data available, particularly the pVO2 results, from the FIX-HF-5 subgroup.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The primary analysis employed a Bayesian repeated measures linear model to estimate group differences in mean pVO2 at 24 weeks from baseline, with 30% borrowing of information (70% down-weighting) from the corresponding treatment group difference observed in the FIX-5 study subgroup. The Bayesian posterior probability would need to be &gt; 0.975 to be considered a positive result with statistical significance.</non_inferiority_desc>
            <p_value>0.975</p_value>
            <p_value_desc>The posterior probability (Pr) that the mean difference in pVO2 (Δ3) between device and control groups is greater than zero must exceed 0.975 to meet the primary effectiveness endpoint.</p_value_desc>
            <method>Bayesian posterior probability</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minnesota Living With Heart Failure (MLWHF) Questionnaire</title>
        <description>Change in quality of life at 24 weeks compared to baseline, as assessed by the Minnesota Living with Heart Failure (MLWHF) Questionnaire. The MLWHFQ score could range from 0 to 105, with higher scores indicating more significant impairment in health-related quality of lif</description>
        <time_frame>24 weeks</time_frame>
        <population>Randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.&#xD;
Optimizer System: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.&#xD;
No intervention: Optimal medical therapy: The control group receives optimal medical therapy only.</description>
          </group>
        </group_list>
        <measure>
          <title>Minnesota Living With Heart Failure (MLWHF) Questionnaire</title>
          <description>Change in quality of life at 24 weeks compared to baseline, as assessed by the Minnesota Living with Heart Failure (MLWHF) Questionnaire. The MLWHFQ score could range from 0 to 105, with higher scores indicating more significant impairment in health-related quality of lif</description>
          <population>Randomized subjects</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.26" spread="24.63"/>
                    <measurement group_id="O2" value="47.47" spread="25.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak VO2 With Respiratory Exchange Ratio (RER)</title>
        <description>Peak VO2 with change in respiratory exchange ratio (RER) included as a covariate, as measured by a blinded core lab.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.&#xD;
Optimizer System: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.&#xD;
No intervention: Optimal medical therapy: The control group receives optimal medical therapy only.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak VO2 With Respiratory Exchange Ratio (RER)</title>
          <description>Peak VO2 with change in respiratory exchange ratio (RER) included as a covariate, as measured by a blinded core lab.</description>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.55" spread="3.51"/>
                    <measurement group_id="O2" value="15.25" spread="3.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>NYHA</title>
        <description>Heart failure class, as assessed by the New York Heart Association (NYHA) classification.</description>
        <time_frame>24 weeks</time_frame>
        <population>Improvement of 1 NYHA class or more.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.&#xD;
Optimizer System: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.&#xD;
No intervention: Optimal medical therapy: The control group receives optimal medical therapy only.</description>
          </group>
        </group_list>
        <measure>
          <title>NYHA</title>
          <description>Heart failure class, as assessed by the New York Heart Association (NYHA) classification.</description>
          <population>Improvement of 1 NYHA class or more.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak VO2 With a Peak RER of ≥1.05</title>
        <description>Peak VO2 in an analysis that only includes tests with a peak RER of ≥1.05.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.&#xD;
Optimizer System: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.&#xD;
No intervention: Optimal medical therapy: The control group receives optimal medical therapy only.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak VO2 With a Peak RER of ≥1.05</title>
          <description>Peak VO2 in an analysis that only includes tests with a peak RER of ≥1.05.</description>
          <units>ml/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="0.96"/>
                    <measurement group_id="O2" value="1.1" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>6 Minute Hall Walk</title>
        <description>Distance walked in 6 minutes</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.&#xD;
Optimizer System: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.&#xD;
No intervention: Optimal medical therapy: The control group receives optimal medical therapy only.</description>
          </group>
        </group_list>
        <measure>
          <title>6 Minute Hall Walk</title>
          <description>Distance walked in 6 minutes</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324" spread="90"/>
                    <measurement group_id="O2" value="317" spread="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>VE/VCO2</title>
        <description>VE/VCO2 measured during cardiopulmonary stress testing (CPX) and evaluated by a blinded core lab.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.&#xD;
Optimizer System: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.&#xD;
No intervention: Optimal medical therapy: The control group receives optimal medical therapy only.</description>
          </group>
        </group_list>
        <measure>
          <title>VE/VCO2</title>
          <description>VE/VCO2 measured during cardiopulmonary stress testing (CPX) and evaluated by a blinded core lab.</description>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="9.0"/>
                    <measurement group_id="O2" value="14.7" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 Weeks Study Period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>The treatment group receives the OPTIMIZER System implant and continues with optimal heart failure medical therapy.&#xD;
Optimizer System: The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>The Control group will not receive the OPTIMIZER System and will continue with optimal heart failure medical therapy.&#xD;
No intervention: Optimal medical therapy: The control group receives optimal medical therapy only.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Heart Failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>General Cardiopulmonary</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Thromboembolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>General Medical</sub_title>
                <counts group_id="E1" events="28" subjects_affected="18" subjects_at_risk="74"/>
                <counts group_id="E2" events="29" subjects_affected="17" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Local Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ICD or Pacemaker System Related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>OPTIMIZER System Related</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmias</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>General Cardiopulmonary Event</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Worsening Heart Failure</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>General Medical</sub_title>
                <counts group_id="E1" events="28" subjects_affected="18" subjects_at_risk="74"/>
                <counts group_id="E2" events="29" subjects_affected="17" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Localized Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ICD or Pacemaker System Related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>OPTIMIZER System Related</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Director, Clinical and Data Operations</name_or_title>
      <organization>Impulse Dynamics (USA) Inc</organization>
      <phone>8453592389</phone>
      <email>angelas@impulse-dynamics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

